NCT07218003 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07218003
Title	A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Rondo Therapeutics
Indications	ureter transitional cell carcinoma cervical cancer lung non-small cell carcinoma renal pelvis transitional cell carcinoma stomach cancer transitional cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma esophageal cancer triple-receptor negative breast cancer
Therapies	RNDO-564 Pembrolizumab + RNDO-564
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Carolina Biooncology	RECRUITING	Huntersville	North Carolina	28078	United States	Details
Sarah Cannon Research Institute, LLD	RECRUITING	Nashville	Tennessee	37203	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07218003Clinical Trial Detail